Disclosure of interest: Nothing to disclose Poster Session I - RECOVERY, REHABILITATION AND OUTCOME 03.00 - RECOVERY, REHABILITATION AND OUTCOME - 03.03 - PROGNOSIS AND OUTCOME AFTER STROKE P262 - ESOC25-1312 DISCHARGE RATES TO HOME FOLLOWING RECURRENT ISCHEMIC STROKE (IS): A REAL-WORLD DATA ANALYSIS ON THE CURRENT PATIENT JOURNEY IN THE US Mark Alberts 1 , Jenny Jiang 2 , Yan Wang 3 , Arimanda Reddy 4 , Haitham Alabsi 5 , Meg Thompson 5 , Merena Henderson 2 , Xiaoyan Li 2 , Priyanka Gaitonde 2 1 Hartford HealthCare, Hartford, United States, 2 Bristol Myers Squibb, Lawrenceville, United States, 3 Analysis Group Inc., Los Angeles, United States, 4 Mu-Sigma, Chicago, United States, 5 Johnson & Johnson, Raritan, United States Background and Aims: A significant proportion of IS patients experience recurrent IS within five years
From a market perspective, the demand for antifungal drugs continues to rise: The market is expected to expand at a compound annual growth rate (CAGR) of 2.81% from 2020 to 2033, with a size of 14.09 billion US dollars in 2024, expected to rise to 14.48 billion US dollars in 2025, and reach 18.08 billion US dollars by 2033 ( Figure 1 ) (Insights, 2025).However, the development and application of antifungal drugs face numerous challenges (Fisher et al., 2018
However, evidence is largely based on experiments with exogenously added antioxidants/reducing agents or pro-oxidants
Must Read: How Laser Tan Removal Can Transform Your Skin
Pivotal role of CD4 + T cells in renal fibrosis following ureteric obstruction
